Insurance Reimbursement Articles
The COVID-19 pandemic that has pushed the U.S. healthcare system to its limits and crippled the economy has brought stark attention to the need for new legislation to lower medication prices.
Life during the COVID-19 pandemic is surreal even after a year. Healthcare organizations are being pressured to do more with less while at the same time contribute revenue to whittle away at staggering losses.
Two court rulings and segments of the proposed OPPS/ASC and PFS rules may require action from providers to recover expenses caused by the COVID-19 pandemic.
Reimbursement for expensive immune globulin (IG) therapies can be challenging and frustrating for providers. Here's a guide to help ensure they are reimbursed for the cost of these medications.
Healthcare costs continue to rise and payment models subsequently evolve, payers nevertheless largely decide which expensive high-investment drugs will be reimbursed and under what circumstances.
